Innova Vascular, Inc. is a medical device company specializing in the development of minimally invasive solutions for vascular thromboembolism. Founded in 2018 and headquartered in Irvine, California, the company aims to enhance patient outcomes by providing innovative devices that address vascular diseases without the need for open surgery. Situated in Southern California, a hub for medical device innovation, Innova Vascular benefits from proximity to leading academic institutions and a rich pool of engineering talent.
Key Strategic Focus
Innova Vascular concentrates on creating advanced medical devices for the treatment of arterial and venous thromboembolism through minimally invasive techniques. Their flagship products include the Laguna Thrombectomy System™, Laguna Clot Retriever™ System, and Malibu Aspiration Catheter™ System, all designed to improve patient outcomes in peripheral vasculature treatments. These devices are engineered to navigate complex vascular anatomies efficiently, facilitating rapid and safe clot removal.
Financials and Funding
As of 2024, Innova Vascular has raised approximately $9 million in funding. In February 2022, the company entered into a partnership with Cardiovascular Systems, Inc. (CSI), which provided financing for the development of a full line of thrombectomy devices. Under this agreement, CSI has exclusive rights to acquire these devices upon completion of key technical, regulatory, and clinical milestones.
Pipeline Development
Innova Vascular's product pipeline features the Laguna Thrombectomy System™, comprising the Laguna Clot Retriever™ and the Malibu Aspiration Catheter™. These devices received U.S. Food and Drug Administration (FDA) 510(k) clearance in June 2023 for use in the peripheral vasculature. Early commercial use began in February 2024, with positive feedback from physicians at UCLA Medical Center and Providence St. Joseph in California.
Technological Platform and Innovation
Innova Vascular's technological innovations include:
- Laguna Clot Retriever™ System: A self-expanding, laser-cut Nitinol device designed for optimal radial strength and flexibility, facilitating effective clot capture and removal.
- Malibu Aspiration Catheter™ System: Features a gradient structural design and hydrophilic coating, enhancing navigability through tortuous vessels and enabling efficient clot aspiration.
These proprietary technologies are tailored to address the challenges of vascular thromboembolism treatment, offering physicians tools that are both effective and user-friendly.
Leadership Team
Dr. Sanjay Shrivastava serves as the Chief Executive Officer and founder of Innova Vascular. With over 20 years in the medical device industry, Dr. Shrivastava has held leadership roles at Johnson & Johnson, BTG plc (acquired by Boston Scientific Corporation), Medtronic, and Covidien/ev3. He co-founded BlackSwan Vascular and serves on the board of directors at enVVeno Medical Corporation. Dr. Shrivastava holds over 30 issued U.S. patents and has edited two books, including "Medical Device Materials."
Board of Directors
- Dr. Owen O’Neill: Orthopedic Surgeon and President of Twin Cities Orthopedics.
- Michael J. Hennessy, Jr.: Chief Executive Officer and President of MJH Life Sciences™.
Competitor Profile
Market Insights and Dynamics
The market for thrombectomy devices is experiencing significant growth, driven by the increasing prevalence of vascular thromboembolism and advancements in minimally invasive treatment options. The global thrombectomy devices market is projected to reach substantial figures, with a compound annual growth rate (CAGR) reflecting the rising demand for effective vascular interventions.
Competitor Analysis
Key competitors in the thrombectomy device market include:
- Okami Medical: Develops devices for the occlusion of peripheral vessels, focusing on innovative and intuitive solutions.
- Artio Medical: Specializes in medical devices designed for immediate occlusion of aneurysms and blood vessels, emphasizing deliverability and precision placement.
- REVA Medical: Focuses on bioresorbable polymer technologies for vascular applications, including scaffolds for peripheral and coronary artery disease.
These companies contribute to a competitive landscape marked by rapid technological advancements and a focus on improving patient outcomes through minimally invasive procedures.
Strategic Collaborations and Partnerships
In May 2024, Innova Vascular entered into an exclusive U.S. distribution agreement with Varian, a Siemens Healthineers company, for the Laguna Thrombectomy System™. This partnership aims to expand options for venous thromboembolism management and integrate advanced imaging with interventional therapies.
Operational Insights
Innova Vascular's strategic partnerships, such as those with Cardiovascular Systems, Inc. and Varian, enhance its market position by leveraging established distribution networks and technological synergies. The company's focus on user-friendly, effective devices positions it competitively in the rapidly evolving thrombectomy market.
Strategic Opportunities and Future Directions
Looking ahead, Innova Vascular plans to continue developing innovative products for clot removal, explore collaborations with prominent organizations, and potentially pursue acquisition opportunities to further its mission of advancing minimally invasive vascular treatments.
Contact Information
- Website: Innova Vascular
- Email: info@innovavascular.com
- Headquarters: Irvine, California
